Clinical Trials on Human Papillomavirus 16 in Belgium

Total 357 results

University Hospital, Ghent

Completed

Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) (HPVXneutra001)

Infection With Human Papillomavirus

Belgium
Janssen Vaccines & Prevention B.V.
Bavarian Nordic

Terminated

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Human Papillomavirus Infections

United States, Belgium
Universiteit Antwerpen

Completed

Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (ABSOP-FollowUp)

Human Papilloma Virus Infection

Belgium
Cesa Projects International

Unknown

AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections

Genital Human Papilloma Virus Infection

Belgium
Universiteit Antwerpen
Research Foundation Flanders

Completed

Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study) (AB-SOP)

Human Papilloma Virus Infection

Belgium
Universiteit Antwerpen

Completed

Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples (HPV-VACPLUS)

Human Papilloma Virus Infection

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Infections, Papillomavirus | Papillomavirus Vaccines

Belgium
GlaxoSmithKline

Completed

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

Infections, Papillomavirus | Papillomavirus Vaccines

Belgium, United States
GlaxoSmithKline

Completed

Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)

Infections, Papillomavirus

Belgium
Universitair Ziekenhuis Brussel

Active, not recruiting

Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis

Human Papilloma Virus

Belgium
Centre Hospitalier Universitaire Saint Pierre

Active, not recruiting

Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study) (Papillon)

HIV Infections | HPV - Anogenital Human Papilloma Virus Infection

Belgium
Erasme University Hospital

Completed

Comparison Between Three Freezing Protocols to Preserve Human Embryos

Human Embryo Cryopreservation

Belgium
Labo'Life

Recruiting

Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections. (PAPION)

Human Papilloma Virus

Belgium
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Infections, Papillomavirus

Belgium, United States
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts

Austria, Belgium, Finland, Germany, Italy, Spain
Universitaire Ziekenhuizen KU Leuven
Innovative Medicines Initiative; BELpREG

Recruiting

UmbrelLACT Study: Clinical Lactation Study on the Exposure to Medicines Via Human Milk (UmbrelLACT)

Breast Feeding | Human Milk

Belgium
University Hospital, Ghent

Completed

A Trial Investigating the Effect of a Treatment With Zinkgluconaat for Verrucae Vulgares

Verrucae Vulgares

Belgium
Universiteit Antwerpen

Completed

A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts (OVW-SA001)

Cutaneous Warts

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

Human Influenza

Belgium
University Hospital, Ghent
University Ghent

Completed

Reparation of Cartilage Injuries in the Human Knee by Implantation of Fresh Human Allogenic Chondrocytes

Cartilage Injuries in the Human Knee

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

Human Influenza

Belgium
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

Human Influenza

Belgium
Universitair Ziekenhuis Brussel

Completed

HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles

Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing IUI

Belgium
Merck Sharp & Dohme LLC

Completed

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

Papilloma Viral Infection

Belgium, Germany, Netherlands
Université Catholique de Louvain
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Optimization of Darunavir Therapy and Dosage Recommendations

Human Immunodeficiency Virus I Infection

Belgium
Pfizer

Completed

Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants

Healthy Volunteers | Adult | Drug Interactions | Humans

Belgium
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
GlaxoSmithKline
University Ghent

Completed

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

HIV Infections | Infection, Human Immunodeficiency Virus

Belgium
Universitaire Ziekenhuizen KU Leuven

Completed

Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

Hiv | Human Papilloma Virus | Organ Transplants

Belgium
GlaxoSmithKline

Withdrawn

Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®

Hepatitis A

Belgium
Crucell Holland BV

Completed

Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine

Hepatitis A

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule

Hepatitis A

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

Hepatitis A

Belgium
Cyril Barbezange
Sciensano; Belgian Federal Public Service, Food Chain Safety and Environment; Agentschap Zorg en Gezondheid

Enrolling by invitation

Zoonotic Influenza Surveillance in Belgium (ZOOIS)

Influenza, Human

Belgium
Osivax
Aepodia

Completed

Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects

Influenza

Belgium
GlaxoSmithKline

Completed

Revaccination With Influenza Vaccine GSK1247446A

Influenza | Influenza, Human

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Influenza

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' FluLaval® TF

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults

Influenza

Belgium
Université Catholique de Louvain

Completed

In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome

Human Volunteers

Belgium
Universiteit Antwerpen
Yakult Honsha Co., LTD

Completed

Study of the Effect of Probiotics on Respiratory Morbidity After Influenza Vaccination of Elderly in Nursing Homes

Respiratory Tract Infections

Belgium
LiteVax BV
University Hospital, Ghent

Completed

Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin (TETRALITE-I)

Influenza

Belgium
Vaccitech (UK) Limited

Completed

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Influenza

Belgium

3

Subscribe